Isoniazide Costero

Isoniazid, the active ingredient in Isoniazide Costero, is an antitubercular presented as an oral tablet for oral use. It is employed in the treatment of active tuberculosis and in prophylaxis of latent Mycobacterium tuberculosis infection in adults and children through standard multidrug regimens under medical supervision.

GNH USA supplies Isoniazide Costero as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution in multiple regions.

Isoniazide Costero (isoniazid) is used in the antitubercular therapeutic pathway to manage Mycobacterium tuberculosis infection. - Active tuberculosis: contributes to bactericidal activity as part of combination therapy to achieve cure. - Latent tuberculosis infection: provides prophylaxis to prevent progression to active disease. - Tuberculosis exposure prophylaxis: reduces risk of developing active TB in individuals with recent exposure.

Isoniazid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Peripheral neuropathy: tingling or numbness, especially in extremities. - Hepatotoxicity: elevated liver enzymes and possible jaundice. - Nausea and vomiting: gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hepatitis: jaundice, fatigue, dark urine requiring immediate medical attention. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Seizures: rare neurologic events, particularly in overdose.

Before initiating therapy, several safety considerations should be observed. - Liver monitoring: check baseline and periodic liver function tests during therapy. - Vitamin B6 supplementation: co‑administer pyridoxine to reduce risk of neuropathy. - Alcohol avoidance: limit alcohol intake to decrease hepatic stress. - Renal impairment: adjust dose in patients with severe renal dysfunction. - Pregnancy and lactation: evaluate risk‑benefit before use. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Isoniazide Costero can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampicin: induces hepatic enzymes, reducing isoniazid plasma levels and efficacy. - Anticonvulsants (phenytoin, carbamazepine): increase hepatotoxic risk and lower drug concentrations. - Alcohol: synergistic hepatotoxicity leading to severe liver injury.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., erythromycin): may raise isoniazid levels, requiring monitoring. - Sulfonamide drugs: combined use can enhance hepatic toxicity. - Warfarin: isoniazid may potentiate anticoagulant effect, necessitating INR monitoring.